Forte Biosciences Inc美股招股说明书(2026-04-09版)

5,709,936 Shares of Common Stock We are offering 5,709,936 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and accompanyingprospectus in this offering. The public offering price for each share of common stock is $26.27. Our common stock is listed on the Nasdaq Capital Market(“Nasdaq”) under the symbol “FBRX.” On April8, 2026, the last reported sale price ofour shares of common stock on Nasdaq was $26.27 per share. We are a “smaller reporting company” under applicable Securities and Exchange Commission (“SEC”) rules and, as such, have elected to complywith certain reduced public company disclosure requirements in this prospectus supplement and future filings. See the section entitled “ProspectusSupplement Summary— Implications of Being a Smaller Reporting Company.” Investing in our securities involves significant risks. Please read the information contained under the heading“Risk Factors” beginning on page S-8 of this prospectus supplement, and under similar headings in our filings with theSEC that are incorporated by reference into this prospectus supplement and the accompanying prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities orpassed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is acriminal offense. PerShareTotalPublic offering price$26.27$150,000,018.72Underwriting discounts and commissions(1)$1.5762$9,000,001.12Proceeds, before expenses, to us$24.6938$141,000,017.60 (1)See “Underwriting” beginning on page S-22 of this prospectus supplement for additional information regarding the compensation payable to theunderwriters. We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to an additional856,490 shares of our common stock from us at the public offering price, less underwriting discounts and commissions. The underwriters expect to deliver the shares of common stock to purchasers on or about April 10, 2026. Joint Book-Running Managers GuggenheimSecurities Barclays Prospectus supplement dated April 8, 2026 Table of Contents TABLE OF CONTENTS Preliminary Prospectus Supplement About This Prospectus SupplementProspectus Supplement SummaryThe OfferingRisk FactorsCautionary Note Regarding Forward-Looking StatementsUse of ProceedsDividend PolicyDilutionMaterial U.S. Federal Income Tax ConsiderationsUnderwritingLegal MattersExpertsWhere You Can Find More InformationInformation Incorporated by Reference Prospectus About This ProspectusProspectus SummaryRisk FactorsForward-Looking StatementsUse of ProceedsDescription of Capital StockDescription of Debt SecuritiesDescription of Depositary SharesDescription of WarrantsDescription of Subscription RightsDescription of Purchase ContractsDescription of UnitsPlan of DistributionLegal MattersExpertsWhere You Can Find More InformationIncorporation by Reference Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus relate to the offering of our common stock. Before buying any of the common stockthat we are offering, we urge you to carefully read this prospectus supplement, the accompanying prospectus, any free writing prospectus that we haveauthorized for use in connection with this offering, and the information incorporated by reference as described under the headings “Where You Can FindMore Information” and “Information Incorporated by Reference” in this prospectus supplement. These documents contain important information thatyou should consider when making your investment decision. This prospectus supplement and the accompanying prospectus are part of a “shelf” registration statement on Form S-3 (File No.333-286226) thatbecame effective on April3, 2025. This document is comprised of two parts. The first part is this prospectus supplement, which describes the specificterms of this offering and also adds to, and updates information contained in, the accompanying prospectus and the documents incorporated by referenceinto this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, including the documentsincorporated by reference into the accompanying prospectus, provides more general information, some of which may not apply to this offering.Generally, when we refer to this prospectus, we are referring to the combined document consisting of this prospectus supplement and the accompanyingprospectus. In this prospectus supplement, as permitted by law, we “incorporate by reference” information from other documents that we file with theSEC. This means that we can disclose important information to you by referring to those documents. The information incorporated by reference isconsidered to be a part of this prospectus supplement and the accompanying prospectus and shou